Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

1.3. Revenue and recurring EBITDA

1.5 Royalty income and fees

1.5 Royalty income and fees

 

Actual

Variance

€ million

2020

2019

Actual rates

CER

Biotechnology IP

60

38

57%

60%

Toviaz®

18

19

-3%

0%

Other

18

22

-19%

-18%

Royalty income and fees

96

78

22%

24%

In 2020, royalty income and fees reached € 96 million after € 78 million.

The biotechnology IP income benefitted from a one-time royalty received while other royalties on marketed products using UCB’s antibody intellectual property remained stable.

The franchise royalties paid by Pfizer for the overactive bladder treatment Toviaz® (fesoterodine) remained stable.